GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Equity-to-Asset

Sinovac Biotech (Sinovac Biotech) Equity-to-Asset

: 0.63 (As of Jun. 2023)
View and export this data going back to 2003. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sinovac Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $8,664.9 Mil. Sinovac Biotech's Total Assets for the quarter that ended in Jun. 2023 was $13,725.0 Mil. Therefore, Sinovac Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.63.

The historical rank and industry rank for Sinovac Biotech's Equity-to-Asset or its related term are showing as below:

SVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39   Med: 0.55   Max: 0.69
Current: 0.63

During the past 13 years, the highest Equity to Asset Ratio of Sinovac Biotech was 0.69. The lowest was 0.39. And the median was 0.55.

SVA's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs SVA: 0.63

Sinovac Biotech Equity-to-Asset Historical Data

The historical data trend for Sinovac Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.65 0.39 0.56 0.63

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.56 0.63 0.63 0.63

Competitive Comparison

For the Biotechnology subindustry, Sinovac Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Equity-to-Asset falls into.



Sinovac Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sinovac Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=8921.421/14114.568
=0.63

Sinovac Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=8664.871/13725.01
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (NAS:SVA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sinovac Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022

Sinovac Amends Shareholder Rights Plan

By Business Wire Business Wire 02-22-2023